Data regarding an innovative bispecific antibody – CPL-976 (CPBT-0976) – were recently reported by Celon Pharma SA. Bispecific antibodies targeting more than one antigen on cancer cells improve the specificity and effectiveness of the therapy, and could be utilized for targeting the defense mechanisms of cancer cells, such PD-L1 or EGFR, VEGFR and AXL.
The checkpoint kinase WEE1 catalyzes the inhibition of cell cycle progression and CDK1 phosphorylation. WEE1 inhibitors have demonstrated clinical benefits in gynecological malignancies, yet limited antitumor activity and a multifaceted toxicity profile of small-molecule inhibitors mean new approaches to target WEE1 are needed.
Researchers from Revolution Medicines Inc. presented the discovery and preclinical characterization of RMC-5127, a novel noncovalent, tri-complex inhibitor of GTPase KRAS (G12V mutant), or KRAS G12V(ON).
RSS
